grant
Phenotypic variability within isogenic population of lymphocytes
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025AddressAntigen ReceptorsAntigensAntioncogene Protein p53AssayAutoantigensAutologous AntigensBioassayBiochemicalBiological AssayBiologyBody TissuesCCRCD8CD8BCD8B1CD8B1 geneCancer cell lineCell BodyCell Communication and SignalingCell SignalingCellsCellular Tumor Antigen P53Clinical TrialsCognitive DiscriminationCollaborationsCommunicationComputer ModelsComputerized ModelsDifferential Algebraic EquationDifferential EquationDiscriminationDown-RegulationERBB2ERBB2 geneEngineeringFeedbackFuzzy LogicHCPHHER -2HER-2HER2HER2 GenesHER2/neuHematopoietic Cell PhosphataseHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHeterogeneityHumanImmune mediated therapyImmune responseImmunologically Directed TherapyImmunotherapyIntracellular Communication and SignalingKinasesKineticsLYT3LeadLegal patentLigandsLogicLung ParenchymaLung TissueLymphatic cellLymphocyteLymphocyticMHC ReceptorMajor Histocompatibility Complex ReceptorMalignant Hematopoietic NeoplasmMapsMethodologyModelingModern ManNEU OncogeneNEU proteinNatureNonreceptor Type 6 Protein-Tyrosine PhosphataseOncogene ErbB2Oncoprotein p53P53PTP-1CPTP1CPTPN6PTPN6 genePatentsPathway interactionsPb elementPeptidesPhasePhenotypePhosphatasesPhosphohydrolasesPhosphomonoesterasesPhosphoprotein P53Phosphoprotein pp53Phosphoric Monoester HydrolasesPhosphotransferase GenePhosphotransferasesPopulationProtein TP53Protein-Tyrosine Phosphatase 1CProteinsProviderReceptor ActivationReceptor ProteinReceptor SignalingRegulationRoboticsSHP-1ScienceSelf ToleranceSelf-AntigensShapesSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSortingSpecificitySpeedStructure of parenchyma of lungSystemT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT-Cell ActivationT-Cell Antigen ReceptorsT-Cell ReceptorT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTKR1TP53TP53 geneTRP53TestingTheoretic ModelsTheoretical modelTissuesToxic effectToxicitiesTransphosphorylasesTumor CellTumor Protein p53Tumor Protein p53 GeneTyrosine phosphatase SHP1ValidationWorkactivate T cellsantagonismantagonistantigen-specific T cellsbiological signal transductionblood cancerc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer of bloodcancer of the bloodchimeric antigen receptorcomputational modelingcomputational modelscomputer based modelscomputerized modelingdigitalengineered T cellserbB-2 Genesgenetically engineered T-cellsheavy metal Pbheavy metal leadherstatinhost responseimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunoresponseleukemialymph cellmouse modelmurine modelneo-antigenneo-epitopesneoantigensneoepitopesneoplastic cellneu Genesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnonbinarynovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyp53 Antigenp53 Genesp53 Tumor Suppressorpathwayphenomenological modelsphenomenologypreservationprotein p53receptorreceptor functionresponsesingle cell analysissmall molecular inhibitorsmall molecule inhibitorthymus derived lymphocytetransgenic T- cellstumortumor specificityvalidations
Description preview
We expanded the project horizon by collaborating with Naomi Taylor (CCR) and Paul François (UMontréal) in order to usher new Chimetic Antigen Receptor (CAR) T cells. CAR T cell therapy has been transformative for blood cancers but remains limited in treating solid tumors due to on-target/off-tumor (OTOT) toxicity. To address this, we engineered T…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click